Prostate Cancer Therapeutics Market Size, Share & Industry Analysis, By Drug Class (Androgen Receptor & Microtubule Inhibitors, Gonadotropin Releasing Hormone (GnRH) Agonist, Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist), By Route of Administration (Oral & Parenteral), By Therapy (Chemo, Hormonal, Targeted, and Immuno Therapy), By Disease State (Metastatic Castration-Resistant Prostate Cancer & Non-Metastatic Castration-Resistant Prostate Cancer), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, & Online Pharmacies), and Regional Forecast, 2025-2032

Last Updated: November 17, 2025 | Format: PDF | Report ID: FBI112008

To get information on various segments, share your queries with us

ATTRIBUTE	DETAILS
Study Period	2019-2032
Base Year	2024
Estimated Year	2025
Forecast Period	2025-2032
Historical Period	2019-2023
Unit	Value (USD Billion)
Growth Rate	CAGR of 22.16% from 2025-2032
Segmentation	By Drug Class Androgen Receptor Inhibitors Microtubule Inhibitors Gonadotropin Releasing Hormone (GnRH) Agonist Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist Others
	By Route of Administration Oral Parenteral
	By Therapy Chemotherapy Hormonal Therapy Targeted therapy Immunotherapy
	By Disease State Metastatic Castration-Resistant Prostate Cancer Non-Metastatic Castration-Resistant Prostate Cancer
	By Distribution Channel Hospital Pharmacies Drug Stores & Retail Pharmacies Online Pharmacies
	By Region North America (By Drug Class, Route of Administration, Therapy Type, Disease State, Distribution Channel, and Country) U.S. Canada Europe (By Drug Class, Route of Administration, Therapy Type, Disease State, Distribution Channel, and Country/Sub-Region) U.K. Germany France Spain Italy Rest of Europe Asia Pacific (By Drug Class, Route of Administration, Therapy Type, Disease State, Distribution Channel, and Country/Sub-Region) Japan China India Australia Rest of Asia Pacific Latin America (By Drug Class, Route of Administration, Therapy Type, Disease State, Distribution Channel, and Country/Sub-Region) Brazil Mexico Rest of Latin America Middle East & Africa (By Drug Class, Route of Administration, Therapy Type, Disease State, Distribution Channel, and Country/Sub-Region) GCC South Africa Rest of the Middle East & Africa